前十大AH股溢价率排行 智通财经APP获悉，截止8月4日收盘，东北电气(00042)、弘业期货(03678)、中石化油服(01033)分列AH 溢价率前三位，溢价率分别为831.03%、243.94%、213.16%；宁德时代(03750)、恒瑞医药(01276)、招 商银行(03968)分列AH溢价率末三位，溢价率分别为-23.53%、-6.00%、5.45%。其中安德利果汁 (02218)、金力永磁(06680)、弘业期货(03678)的偏离值位居前三，分别为31.31%、17.69%、15.76%；另 外，东北电气(00042)、中国人寿(02628)、国联民生(01456)的偏离值位居后三，分别 为-77.80%、-28.53%、-26.73%。 | 股票名称 | H股(港元) | A股 | 溢价率 | 偏离值↓ | | --- | --- | --- | --- | --- | | 安德利果汁(02218) | 18.190 | 47.25 | 211.16% | 31.31% | | 金力永磁(06680) | 18.500 | 27.01 | 74.86% | 17.69% | | 弘业期货(0 ...

Group 1 - Heng Rui Medicine (01276) experienced a rebound of over 3% in early trading, with a current stock price of 77.35 HKD and a trading volume of 254 million HKD [1] - Heng Rui has reached a cooperation agreement with GSK regarding HRS-9821 and up to 11 other projects, granting GSK exclusive licensing rights for overseas rights [1] - GSK will pay Heng Rui 500 million USD as part of the agreement, indicating significant financial backing for the projects involved [1] Group 2 - The PDE3/4 inhibitor, HRS-9821, is currently in clinical development and is considered a high-potential target for treating chronic obstructive pulmonary disease (COPD) [1] - According to Guosheng Securities, the potential of PDE3/4 inhibitors is substantial, and the business development (BD) transaction is expected to enhance Heng Rui's performance [1]

截止8月1日收盘，东北电气(00042)、弘业期货(03678)、安德利果汁(02218)分列AH溢价率前三位，溢价 率分别为800.00%、237.59%、222.93%；宁德时代(03750)、恒瑞医药(01276)、招商银行(03968)分列AH 溢价率末三位，溢价率分别为-21.81%、-0.69%、5.79%。其中安德利果汁(02218)、金力永磁(06680)、 昭衍新药(06127)的偏离值位居前三，分别为44.34%、22.81%、15.64%；另外，比亚迪股份(01211)、东 北电气(00042)、中州证券(01375)的偏离值位居后三，分别为-203.14%、-115.57%、-30.23%。 前十大AH股溢价率排行 | 股票名称 | H股(港元) | A股 | 溢价率↓ | 偏离值 | | --- | --- | --- | --- | --- | | 东北电气(00042) | 0.300 | 2.25 | 800.00% | -115.57% | | 弘业期货(03678) | 4.230 | 11.92 | 237.59% | 9.55% | | 安德利果汁(02218) | 1 ...

Core Viewpoint - The strategic partnership between Heng Rui Medicine and GlaxoSmithKline (GSK) marks a significant milestone in the internationalization of Chinese pharmaceutical companies, with a potential total deal value of up to $12 billion, reflecting a qualitative change in their position within the global pharmaceutical value chain [1][6]. Group 1: Partnership Details - Heng Rui will receive an upfront payment of $500 million from GSK, with the core project being the PDE3/4 inhibitor HRS-9821, currently in clinical development for chronic obstructive pulmonary disease (COPD) [2][3]. - The agreement allows Heng Rui to license HRS-9821 globally outside of mainland China and Hong Kong, with the potential for developing a convenient dry powder inhaler (DPI) formulation [3][4]. - The collaboration includes a scalable cooperation plan to jointly develop up to 11 additional projects, with Heng Rui leading the research and GSK retaining global development and commercialization options after Phase I trials [4][5]. Group 2: Strategic Implications - This partnership is a testament to Heng Rui's international recognition of its innovative capabilities and represents a significant step in its globalization efforts [4][5]. - For GSK, the collaboration aligns with its strategy of leveraging validated targets, allowing it to expand its research pipeline while mitigating development risks [5][6]. - The deal reflects a shift in the global pharmaceutical landscape, where Chinese companies are transitioning from being mere technology suppliers to equal partners in the global innovation network [1][6]. Group 3: Industry Transformation - The transaction highlights the evolving strategies of Chinese pharmaceutical companies, moving towards more flexible financial arrangements and performance-based payment mechanisms [6][8]. - The partnership with Hercules, where Heng Rui acquired a 19.9% stake, signifies a shift from asset sales to capital integration, creating a deeper bond between partners [7][8]. - The overall restructuring of the global pharmaceutical value chain is driven by geopolitical factors and the need for diversified global sales networks, with Chinese companies increasingly becoming rule-makers in the industry [8][9].

Performance Updates - 开拓药业-B (09939.HK) has completed patient enrollment for the Phase III clinical trial of KX-826 solution for androgenetic alopecia in adult males in China [2] - 李氏大药厂 (00950.HK) has received approval from the National Medical Products Administration for Socazolimab to be used in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer in mainland China [2] - 恒瑞医药 (01276.HK) has received approval for clinical trials of SHR-8068 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [2] - 恒瑞医药 (01276.HK) has also received approval to conduct clinical trials for HRS-5041, intended for prostate cancer treatment [2] - 深圳高速公路股份 (00548.HK) reported toll revenue of 106 million yuan for the outer ring project in June [2] - 大成生化科技 (00809.HK) has signed an EPC contract with Northeast Electric and Liaoning Electric for boiler renovation projects, with a maximum cost of 129.1 million yuan [2] - 小黄鸭德盈 (02250.HK) has signed a contract to develop an AI marketing system to diversify revenue sources [2] Buyback and Financing Activities - 威海银行 (09677.HK) plans to issue up to approximately 758 million domestic shares and 154 million H-shares, raising nearly 3 billion yuan [2] Financial Results - 香港电讯-SS (06823.HK) reported total revenue of 17.322 billion HKD for the first half, a year-on-year increase of 4%, with a net profit of 2.07 billion HKD, also up 4% [4] - 青岛银行 (03866.HK) reported operating revenue of 7.662 billion yuan for the first half, a growth of 7.5%, and a net profit of 3.065 billion yuan, up 16.05% [4] - 中国石油化工股份 (00386.HK) expects mid-term net profit to be between 20.1 billion and 21.6 billion yuan, a year-on-year decline of 39.5%-43.7% [4] - 汽车之家-S (02518.HK) reported total revenue of 3.212 billion yuan for the first half, a decrease of 7.75%, with a net profit of 772 million yuan, down 15.99% [4] - 绿茶集团 (06831.HK) issued a profit warning, expecting mid-term net profit to be between 230 million and 237 million yuan, a year-on-year increase of approximately 32%-36% [4] - 粤海置地 (00124.HK) issued a profit warning, expecting mid-term net profit to exceed 260 million HKD, turning from loss to profit [4] - 药师帮 (09885.HK) issued a profit warning, expecting mid-term net profit to exceed 70 million yuan [4] - 中国东方教育 (00667.HK) issued a profit warning, expecting mid-term net profit to grow by 45%-50% year-on-year [4] - 中核国际 (02302.HK) issued a profit warning, expecting mid-term revenue to increase to at least 585 million HKD, with net profit of at least 9.5 million HKD [4] - 大唐环境 (01272.HK) issued a profit warning, expecting mid-term net profit to decrease to between 350 million and 400 million yuan [4] - 长江生命科技 (00775.HK) issued a profit warning, expecting mid-term net loss of approximately 150 million HKD, turning from profit to loss year-on-year [4] - 延长石油国际 (00346.HK) issued a profit warning, expecting mid-term loss of approximately 27.9 million HKD [4]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-5041, a new drug aimed at treating prostate cancer, indicating a significant advancement in its product pipeline [1] Group 1: Product Development - HRS-5041 is a novel, efficient, and selective AR-PROTAC small molecule developed by the company [1] - The drug demonstrates significant degradation effects on wild-type and various mutant AR proteins, showing potential to overcome resistance compared to second-generation AR inhibitors [1] - Currently, there are no similar products approved for market in both domestic and international markets [1] Group 2: Financial Investment - The cumulative research and development investment for the HRS-5041 project has reached approximately 69.19 million yuan [1]

Core Viewpoint - Heng Rui Medicine (01276) has received approval from the National Medical Products Administration for the clinical trial of HRS-5041, a new selective AR-PROTAC small molecule aimed at treating prostate cancer [1] Company Summary - HRS-5041 is designed to effectively degrade androgen receptor (AR) proteins, including various mutant forms, showing significant potential to overcome resistance compared to second-generation AR inhibitors [1] - The total research and development investment for the HRS-5041 project has reached approximately 69.19 million yuan [1] Industry Summary - Currently, there are no similar products approved for market release domestically or internationally, indicating a unique position for HRS-5041 in the prostate cancer treatment landscape [1]

Core Viewpoint - Company has received approval from the National Medical Products Administration for clinical trials of three monoclonal antibody injections, indicating a significant advancement in its oncology pipeline [1][2][3] Group 1: SHR-8068 Injection - SHR-8068 is a fully human anti-CTLA-4 monoclonal antibody aimed at enhancing anti-tumor immune effects, with a total R&D investment of approximately 21.35 million yuan [1] - Currently, there are two similar products approved globally, with combined sales of approximately 3.271 billion USD in 2024 [1] Group 2: Adebali Injection - Adebali injection is a humanized anti-PD-L1 monoclonal antibody that reactivates the immune system's anti-tumor activity, with a total R&D investment of about 90.13 million yuan [2] - The product was approved for use in first-line treatment of extensive-stage small cell lung cancer in March 2023, and similar products have a projected global sales of approximately 9.648 billion USD in 2024 [2] Group 3: Bevacizumab Injection - Bevacizumab is a humanized anti-VEGF monoclonal antibody, with a total R&D investment of around 34.49 million yuan [3] - The global sales forecast for Bevacizumab in 2024 is approximately 5.655 billion USD, indicating a strong market presence [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 孫飄揚先生 中國上海 2025年7月31日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-111 江苏恒瑞医药股份有限公司 关于获得药物临床 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年7月31日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-11 ...